Burzynski Research Institute (BZYR) Current Assets (2011 - 2025)
Burzynski Research Institute (BZYR) posted Current Assets of $2265.0 for Q4 2025, up 70.17% sequentially from $1331.0 in Q3 2025, and up 217.67% YoY from $713.0 in Q4 2024.
Burzynski Research Institute (BZYR) Current Assets (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Current Assets for 15 years, with the latest figure at $2265.0 in Q4 2025.
- Quarterly Current Assets rose 217.67% year-over-year to $2265.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $2265.0 (up 217.67% YoY) and the FY2025 annual result came in at $847.0, down 63.33% from the prior year.
- Current Assets rose to $2265.0 in Q4 2025 per BZYR's latest filing, from $1331.0 in the prior quarter.
- Over five years, Current Assets peaked at $6739.0 in Q4 2021 and troughed at $713.0 in Q4 2024.
- A 5-year average of $2116.0 and a median of $1729.0 in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2021 and 2022: Current Assets plunged 95.18% in 2021, then soared 387.55% in 2022.
- Over 5 years, Current Assets stood at $6739.0 in 2021, then sank by 73.41% to $1792.0 in 2022, then sank by 43.47% to $1013.0 in 2023, then dropped by 29.62% to $713.0 in 2024, then soared by 217.67% to $2265.0 in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $2265.0, $1331.0, and $1521.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 2,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 2,265.00 |
| Aug 31, 2025 | 1,331.00 |
| May 31, 2025 | 1,521.00 |
| Feb 28, 2025 | 847.00 |
| Nov 30, 2024 | 713.00 |
| Aug 31, 2024 | 1,616.00 |
| May 31, 2024 | 997.00 |
| Feb 29, 2024 | 2,310.00 |
| Nov 30, 2023 | 1,013.00 |
| Aug 31, 2023 | 1,797.00 |
| May 31, 2023 | 848.00 |
| Feb 28, 2023 | 1,934.00 |
| Nov 30, 2022 | 1,792.00 |
| Aug 31, 2022 | 1,666.00 |
| May 31, 2022 | 5,466.00 |
| Feb 28, 2022 | 4,661.00 |
| Nov 30, 2021 | 6,739.00 |
| Aug 31, 2021 | 1,840.00 |
| May 31, 2021 | 2,009.00 |
| Feb 28, 2021 | 956.00 |